Biotech | April 12, 2022
ReiThera and Exothera collaborate to develop large-scale, low cost per dose vaccine
Collaboration awarded €3 million grant by the Bill & Melinda Gates Foundation
Collaboration awarded €3 million grant by the Bill & Melinda Gates Foundation
Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle
About 96% of all 15+ population in the country have received at least one Covid-19 vaccine dose while about 83% of 15+ population has received both the doses
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
Makrolon polycarbonate is key to needle-free injections that can stand up to sterilization
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
Supply increase to help meet growing global demand
BVX-0922 to target colorectal cancer under investigator-sponsored IND
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
Subscribe To Our Newsletter & Stay Updated
